Ann Am Thorac Soc. 2025 Oct 28. doi: 10.1513/AnnalsATS.202505-552OC. Online ahead of print.
ABSTRACT
RATIONALE: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with varied effects on mental health (MH) in people with cystic fibrosis (PwCF). Currently published literature has focused primarily on MH diagnoses/symptoms with ETI as opposed to associated pharmacotherapy.
OBJECTIVES: We sought to evaluate the effect of ETI on MH diagnosis and associated pharmacotherapy in both adult and pediatric PwCF.
METHODS: We conducted a multicenter retrospective study in PwCF who started ETI at 7 accredited CF centers. Primary outcomes were rate of MH diagnosis and medication use pre- and post-ETI initiation. Secondary outcomes were rate of MH medication changes and dose adjustments pre-and post-ETI.
MEASUREMENTS AND MAIN RESULTS: Overall, 1,046 PwCF were included, with 453 in the “MH group” because they had either a MH diagnosis and/or MH medication use at any time point post-ETI. MH medication use and diagnosis both significantly increased from baseline at all time points post-ETI initiation.
CONCLUSIONS: The rate of MH medication use increased significantly from baseline at all time points in PwCF not previously prescribed MH medications, while rate of MH medication use remained consistent for those already on medications pre-ETI.
PMID:41151030 | DOI:10.1513/AnnalsATS.202505-552OC
